NEUP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Neuphoria Therapeutics Inc (NEUP) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's financials are in sharp decline, technical indicators are bearish, and there are no positive catalysts or trading signals to suggest a strong entry point. Additionally, the lack of news, analyst ratings, and congressional trading data further weakens the case for investment.
The technical indicators for NEUP are bearish. The MACD is negatively expanding below 0, the RSI is neutral at 27.526, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support levels are at 4.273 and 4.141, while resistance levels are at 4.701 and 4.833. The stock has a 70% chance of declining in the next day (-0.26%), week (-1.59%), and month (-5.01%).
NULL identified. No recent news, trading signals, or positive sentiment from hedge funds, insiders, or analysts.
There is also a lack of trading trends, news, or congressional trading activity to support a bullish case.
In Q2 2026, the company's revenue dropped to 0 (-100% YoY), net income fell to 1,864,092 (-195.92% YoY), EPS decreased to 0.41 (-133.33% YoY), and gross margin dropped to 0 (-100% YoY). These figures indicate significant financial distress.
No analyst ratings or price target changes available for NEUP.
